MICHAEL S. LAUER, MD
Director, Exercise Stress Laboratory, Director of
Clinical Research, Department of Cardiovascular
Medicine, The Cleveland Clinic Foundation;
Contributing Editor, *JAMA*

Coronary artery disease in diabetes: Which (if any) test is best?

On exercise testing, ST changes are not the strongest predictors of risk

I N THE CURRENT ISSUE of the *Cleveland Clinic Journal of Medicine*, Dr. Wackers presents a scholarly and persuasive review arguing for frequent use of stress myocardial perfusion imaging (MPI) in patients with diabetes.[1]

See related article, page 21

Dr. Wackers' argument is based on two points, both worthy of careful consideration. First, diabetes is associated with a marked increase in cardiovascular risk. Second, clinicians caring for patients with diabetes are faced with a number of diagnostic and prognostic testing options, including exercise testing, stress MPI, and stress echocardiography. MPI may have greater incremental prognostic value than exercise testing and is less technically difficult to perform than stress echocardiography. Indeed, there is an extensive literature from many institutions, including ours, showing that MPI is a powerful predictor of risk.[2–4]

PRE-TEST AND POST-TEST RISK

A fundamental principle of diagnostic and prognostic reasoning is that testing is most useful when baseline risk of disease is considered. Classic Bayesian thinking argues that a diagnostic test is valuable only when pre-test risk is intermediate or close to intermediate.

More recent work on the value of noninvasive tests when used for prognostic purposes has focused on targeting risk: that is, when combining pre-test risk with test findings, a test is useful only if post-test risk is high enough that aggressive treatment might arguably reduce risk.[5] Thus, if pre-test risk is very low, even a floridly abnormal test is unlikely to increase post-test risk to a level high enough that therapy should be changed.[2]

SENSITIVITY OF TESTS OVERRATED

With these concepts in mind, let us examine the issue of noninvasive testing in diabetes, particularly in the absence of symptoms or history of coronary events. Diabetes is now classified as a "coronary disease equivalent," meaning that the risk of subsequent cardiac events in asymptomatic patients with diabetes is no lower than in a patient with known coronary disease but no history of diabetes.[6] Hence, baseline risk in diabetes is high enough that an abnormal noninvasive test would be clinically relevant. Although there is overwhelming evidence that diabetes is associated with a markedly increased cardiovascular risk, it is interesting that recent epidemiological reports have suggested that the risk may not be as high as once thought.[7]

Given that patients with diabetes are at increased risk for having cardiovascular disease or for experiencing subsequent cardiovascular events, clinicians caring for these patients are faced with considering referral for noninvasive tests, either for establishing a diagnosis of coronary disease or for assessing risk. Although the reported sensitivity of MPI is very high in diabetes (see **FIGURE 1** of Dr. Wackers' article),[8] one must realize that the reported sensitivity, exceeding 85% is almost certainly biased, because not all patients referred for noninvasive testing subsequently

undergo coronary angiography. A number of groups have shown that failure to account for this "workup bias" leads to a marked inflation of sensitivity and deflation of specificity.[9–12] Once workup bias is accounted for, the true sensitivity of MPI falls to the range of 65%.[11]

Similarly, exercise testing and stress echocardiography also have poor sensitivity for the diagnosis of coronary disease after accounting for workup bias.[10,12]

■ MARKERS OF RISK ON EXERCISE TESTING

The true clinical value of noninvasive testing is its ability to prognosticate, particularly with regard to fatal events.[13] Which test is best for initial evaluation? Although MPI has been shown to be a stronger predictor of risk than exercise testing, most literature comparing the two tests has only considered ST-segment changes as the exercise-test marker of risk. Recent work based on large cohorts from several institutions has demonstrated that there are much stronger predictors of all-cause and cardiovascular death than ST-segments; namely, exercise capacity,[14] chronotropic response,[15] heart rate recovery,[16] and exercise-associated ventricular ectopy.[17] In one comparison with coronary angiography,[14] exercise capacity emerged as a much stronger predictor of death than angiographic extent of disease!

Data derived from general and clinical populations have been shown to apply to patients with diabetes, as well. One recent study of a large cohort of asymptomatic men with diabetes found that exercise capacity and heart rate recovery were strong risk predictors.[18]

■ WHEN IS IMAGING APPROPRIATE?

Given that exercise testing, when properly interpreted, is a very powerful predictor of risk, when is imaging, such as that afforded by echocardiography or MPI, appropriate?

Current guidelines recommend imaging when exercise testing suggests an intermediate risk for coronary events.[19] This recommendation is supported by data from contemporary cohort studies, in which imaging provided relevant prognostic information over and above exercise testing only when the exercise test suggested an intermediate or higher risk.[2]

Among patients for whom imaging is appropriate, two questions face the clinician: should stress be induced by exercise or pharmacologically, and which type of imaging is appropriate? With the possible exception of patients with left bundle-branch block,[19] it is probably preferable to use exercise to induce stress, since that yields additional important prognostic information from measurement of exercise capacity, heart rate responses, and exercise-associated ventricular ectopy. Direct head-to-head comparisons of MPI and stress echocardiography are few, but current data suggest similar test performance when in good hands.[20,21]

If a physician is faced with a patient with diabetes who has no coronary history and has an interpretable electrocardiogram, it is reasonable to choose to send the patient for an exercise test. Should that exercise test reveal a high risk, such as an impaired exercise capacity or an abnormal heart rate recovery, referring the patient for stress MPI or stress echocardiography is appropriate.

A final, and arguably the most critical, component of the analysis of noninvasive testing in asymptomatic patients, with or without diabetes, is whether or not testing improves outcome. Abnormal findings on imaging may subsequently lead to invasive procedures. Despite all the work that has been done to evaluate test performance, we simply do not know whether or not acquiring any of this information actually helps the patient. From the patient's point of view, the key question is whether premature death or myocardial infarction can be prevented or delayed. The only way to know definitively would be to perform a properly designed and powered randomized trial.

To date, no such trial has been performed.[22] That is why most current guidelines do not enthusiastically recommend any kind of noninvasive testing for screening, even in patients with diabetes.[13,19] However, thanks to work by Wackers and colleagues, we may soon have some real evidence to work with. As Wackers mentions in his article, he has successfully completed enrollment of a randomized trial of patients with diabetes in which testing and no-testing strategies are being compared (Detection of Ischemia in Asymptomatic Diabetics, or DIAD).[1] The

Will testing prevent premature death or myocardial infarction?

results of DIAD will not known for several years. In the meantime, the optimal testing strategy in patients with diabetes will remain subject to lively, inferential debate. ◼

◼ REFERENCES

1. **Wackers FT.** Noninvasive testing options in patients with diabetes mellitus and coronary artery disease. Cleve Clin J Med 2004; 71:21–33.
2. **Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS.** Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001; 37:1558–1564.
3. **Hachamovitch R, Berman DS, Shaw LJ, et al.** Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998; 97:535–543.
4. **Hachamovitch R, Berman DS, Kiat H, Cohen I, Friedman JD, Shaw LJ.** Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness. Circulation 2002; 105:823–829.
5. **Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE.** 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996; 27:1007–1019.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.
7. **Lee CD, Folsom AR, Pankow JS, Brancati FL.** Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109:855–860.
8. **Kang X, Berman DS, Lewin HC, et al.** Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J 1999; 138:1025–1032.
9. **Choi BC.** Sensitivity and specificity of a single diagnostic test in the presence of work-up bias. J Clin Epidemiol 1992; 45:581–586.
10. **Froelicher VF, Lehmann KG, Thomas R, et al.** The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography. Ann Intern Med 1998; 128:965–974.
11. **Miller TD, Hodge DO, Christian TF, Milavetz JJ, Bailey KR, Gibbons RJ.** Effects of adjustment for referral bias on the sensitivity and specificity of single photon emission computed tomography for the diagnosis of coronary artery disease. Am J Med 2002; 112:290–297.
12. **Roger VL, Pellikka PA, Bell MR, Chow CW, Bailey KR, Seward JB.** Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. Circulation 1997; 95:405–410.
13. **Gibbons RJ, Balady GJ, Bricker JT, et al.** ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40:1531–1540.
14. **Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE.** Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793–801.
15. **Elhendy A, Mahoney DW, Khandheria BK, Burger K, Pellikka PA.** Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. J Am Coll Cardiol 2003; 42:823–830.
16. **Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS.** Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000; 284:1392–1398.
17. **Frolkis JP, Pothier CE, Blackstone EH, Lauer MS.** Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781–790.
18. **Cheng YJ, Lauer MS, Earnest CP, et al.** Heart rate recovery following maximal exercise testing as a predictor of cardiovascular disease and all-cause mortality in men with diabetes. Diabetes Care 2003; 26:2052–2057.
19. **Klocke FJ, Baird MG, Lorell BH, et al.** ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42:1318–1333.
20. **Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS.** Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280:913–920.
21. **Olmos LI, Dakik H, Gordon R, et al.** Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease. Circulation 1998; 98:2679–2686.
22. **Fowler-Brown A, Pignone M, Pletcher M, Tice JA, Sutton SF, Lohr KN.** Exercise Tolerance Testing to Screen for Coronary Heart Disease: A Systematic Review for the Technical Support for the US Preventive Services Task Force. Ann Intern Med 2004; 104:W9–24.

ADDRESS: *Michael S. Lauer, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail Lauerm@ccf.org.*

CME ANSWERS

Answers to the credit test on page 79 of this issue

1 **C** 2 **B** 3 **A** 4 **D** 5 **B** 6 **E** 7 **B** 8 **D** 9 **C** 10 **B** 11 **C**